ClinicalTrials.gg
CompletedNCT02244632Updated Sep 9, 2020

Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

A Phase 1/2 interventional study of Modufolin (arfolitixorin) and Fluorouracil in Colorectal Neoplasm, sponsored by Isofol Medical AB. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Enrollment
49th of 132
105 · median 66
Started
2014
with 2 others
Phase 1/2
7 of 159
1 open now
Registered
123rd of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 49th largest by enrollment of the 132 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 1/2, and was the 123rd registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose is to characterise the tolerability of Modufolin (arfolitixorin) in combination with 5-FU alone, in combination with 5-FU and Oxaliplatin, in combination with 5-FU and Irinotecan and in combination with 5-FU, Oxaliplatin and Bevacizumab.

Another purpose is to investigate 4 doses of Modufolin to identify the best dose for further assessment.

Read the detailed description

The study will investigate the tolerability of Modufolin at four (4) different dose levels (30 to 240 mg/m2) in therapy combinations with the chemotherapeutic agents 5-FU, Oxaliplatin +/- bevcizumab, and Irinotecan.

When the selected phase 2 dose is determined, 40 additional patients, will be included in the study in order to acquire more data on the safety and tolerability of Modufolin at this dose level. Twenty (20) of these additional patients will be treated in with Oxaliplatin, 20 with Irinotecan.

03

Conditions studied

  • Colorectal Neoplasm

Keywords

  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal tumors
  • Intestinal Neoplasm
  • Gastrointestinal Neoplasm
  • Gastrointestinal disease
  • 5,10-methylenetetrahydrofolate
  • Tetrahydrofolates
  • Therapeutic uses
  • Pharmacokinetics
  • Pharmacodynamics
  • Safety assessments
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Advanced colorectal (Stage IV) cancer verified by

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Modufolin / Nordic FLV

    Modufolin in combination with 5-Fluorouracil only.

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil

  • Experimental
    Modufolin / Nordic FLOX

    Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin

  • Experimental
    Modufolin / Nordic FLIRI

    Modufolin in combination with 5-Fluorouracil and Irinotecan.

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Irinotecan

  • Experimental
    MOFOX

    Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin

  • Experimental
    MOFOX / Bevacizumab

    Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Oxaliplatin · Drug: Bevacizumab

  • Experimental
    MOFIRI

    Modufolin in combination with 5-Fluorouracil and Irinotecan

    Drug: Modufolin (arfolitixorin) · Drug: Fluorouracil · Drug: Irinotecan

Interventions

  • IV injection every second week for 8 weeks.

    Also known as: [6R] 5,10-methylenetetrahydrofolate, 6R-MTHF, 6R-methylene THF, ISO-901, arfolitixorin

  • IV injection every second week for 8 weeks.

    Also known as: 5-FU, 5-Flourouacil, 5-Fluoro-1H,3H-pyrimidine-2,4-dione, Adrucil

  • IV infusion every second week for 8 weeks.

    Also known as: Eloxatin, [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-O,O')platinum(II), Olatin, Oxamed, Oxitropic

  • IV infusion every second week for 8 weeks.

    Also known as: (+)-(4S)-4,11-Dietyl-4-hydroxi-9-[(4-piperidinopiperidino)karbonyloxi]-1H-pyrano[3¢,4¢:6,7]indolizino[1,2-b]kinolin-3,14-(4H,12H)dion, Irinosor, Campto, Namedica

  • IV infusion every second week for 8 weeks.

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Frequency and severity of dose limiting toxicity (DLT) or other Adverse Events (AE)

    Primary safety variables will consist of monitoring and recording of DLTs and any significant AE that have led to adjustments in the therapy administration.

    Time frame: The patients will be followed during 4 cycles of treatment (8 weeks).

07

Study locations

10 sites
  • Odense University Hospital
    Odense, Denmark
  • 251 General Airforce Hospital
    Athens, Greece
  • Medical School University of Athens, Aretaieio Hospital
    Athens, Greece
  • Metropolitan General Hospital
    Athens, Greece
  • University Genral Hospital Attikon
    Athens, Greece
  • University General Hospital of Heraklion
    Iráklion, Greece
  • Oslo University Hospital - Radiumhospitalet
    Oslo, Norway
  • Oslo University Hospital - Ullevål
    Oslo, Norway
  • Sahlgrenska University Hospital
    Göteborg, 461 85, Sweden
  • Skaraborg hospital
    Skövde, Sweden
08

References and documents

Publications

  • Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Braendengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer. ESMO Open. 2022 Oct;7(5):100589. doi: 10.1016/j.esmoop.2022.100589. Epub 2022 Sep 29. PubMed 36183444 ↗
  • Taflin H, Odin E, Carlsson G, Tell R, Gustavsson B, Wettergren Y. Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. Cancer Chemother Pharmacol. 2021 Jan;87(1):31-41. doi: 10.1007/s00280-020-04173-2. Epub 2020 Oct 24. PubMed 33099678 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jan 2020, 64 months.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's 64 months is close to that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2014
First posted
Sep 19, 2014
StartActual
Sep 2014
Primary completionActual
Jan 30, 2020
CompletionActual
Jan 30, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02244632
Lead sponsor
Isofol Medical AB
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
Sep 2014
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Sep 9, 2020

Study contacts

Göran Carlsson, MD
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: L-(+)-methylenetetrahydrofolic acid · Fluorouracil

Start the discussion